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In order to investigate differences in drug solubilisation and dissolution in luminal fluids of 20 
Crohn’s disease (CD) patients and healthy subjects, biorelevant media representative of CD 21 
patients were developed using information from literature and a Design of Experiment (DoE) 22 
approach. The CD media were characterised in terms of surface tension, osmolality, dynamic 23 
viscosity and buffer capacity and compared to healthy biorelevant media. To identify which 24 
drug characteristics are likely to present a high risk of altered drug solubility in CD, the 25 
solubility of six drugs was assessed in CD media and solubility differences were related to drug 26 
properties. Identified differences in CD patients compared to healthy subjects were a reduced 27 
concentration of bile salts, a higher gastric pH and a higher colonic osmolality. Differences in 28 
the properties of CD compared to healthy biorelevant media were mainly observed for surface 29 
tension and osmolality. Drug solubility of ionisable compounds was altered in gastric CD 30 
media compared to healthy biorelevant media. For drugs with moderate to high lipophilicity, a 31 
high risk of altered drug solubilisation in CD is expected, since a significant negative effect of 32 
log P and a positive effect of bile salts on drug solubility in colonic and fasted state intestinal 33 
CD media was observed. Simulating the conditions in CD patients in vitro offers the possibility 34 
to identify relevant differences in drug solubilisation without conducting expensive clinical 35 
trials.  36 
 37 
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1. Introduction 41 
Inflammatory bowel disease (IBD) is an incurable autoinflammatory disorder that affects about 42 
3.7 million people in Europe (Burisch et al., 2013). While the aetiology of IBD is still unknown, 43 
a combination of factors (environment, genetics, microbiota) is expected to contribute to the 44 
disease (Stefanelli et al., 2008). The two main types of IBD are Crohn’s disease (CD) and 45 
Ulcerative colitis. CD is characterised by transmural discontinuous ulcerations that can affect 46 
any part of the gastrointestinal (GI) tract. Typical symptoms that patients experience are 47 
abdominal pain and cramps, fatigue, fever, weight loss and diarrhoea with passage of blood 48 
and/or mucus (Baumgart and Sandborn, 2012). Within the first 20 years after CD diagnosis, 49 
50% of patients present complications such as strictures, fistulas, abscesses or obstructions 50 
(Baumgart and Sandborn, 2012). These complications often necessitate surgeries and bowel 51 
resections (Rutgeerts, 2004). Apart from the affected gastrointestinal tract, extraintestinal 52 
symptoms are also common in CD patients including inflammations of the eyes such as uveitis 53 
or episcleritis, certain skin conditions such as pyoderma gangrenosum and joint diseases such 54 
as ankylosing spondylitis (Hedin et al., 2019). Therefore, CD necessitates a long-term drug 55 
therapy adapted to the disease localisation and disease state (relapse or remission). 56 
The oral route of drug administration is still the mainstay for patients with CD. Biological 57 
medicines (e.g., anti-tumor necrosis factor α and anti-integrin agents) with subcutaneous or 58 
intravenous administration are only indicated when other treatment options failed. 59 
Recommended oral therapies for CD patients include 5-aminosalicylates (e.g., sulfasalazine, 60 
mesalamine), traditional corticosteroids (e.g., prednisone), budesonide, antibiotics (e.g., 61 
metronidazole) and immunosuppressive agents (e.g., azathioprine) (Talley et al., 2011). To 62 
locally treat the disease in the GI tract, special drug delivery systems have been developed to 63 
deliver the drug to the affected GI compartment (Ma et al., 2019). Apart from medication for 64 
the GI condition, IBD patients also used other drug classes such as antidepressants, antibiotics 65 
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and nonsteroidal anti-inflammatory analgesics more frequently compared to the general 66 
population (Haapamaki et al., 2013).  67 
For concomitant medications, the GI environment of CD patients may impact drug delivery 68 
and absorption. To reach the systemic circulation, orally administered drugs must be released 69 
from the pharmaceutical formulation, dissolve in the GI fluids, permeate the GI membrane and 70 
escape luminal degradation, gut wall and hepatic metabolism. These processes depend on the 71 
physiological conditions in the GI tract. Alterations of the physiological conditions due to 72 
disease states, can impact on drug product performance, which was observed for several drugs 73 
in GI disease patients with local and systemic action (Bai et al., 2016; Effinger et al., 2019; 74 
Hatton et al., 2018, 2019). For poorly soluble compounds, classified according to the 75 
Biopharmaceutics Classification System (BCS) in class II or IV, drug absorption can be 76 
solubility- or dissolution rate-limited (Amidon et al., 1995). Differences in the composition of 77 
the GI fluids such as pH, osmolality, bile salt and lecithin concentrations can impact on these 78 
rate-limiting steps and thus, affect drug absorption (Khadra et al., 2015; Zhou et al., 2017). 79 
Pathophysiological changes in CD may alter the composition of the luminal fluids in the GI 80 
tract of CD patients and therefore, potentially result in altered drug product performance. 81 
Differences in drug product performance in GI disease patients compared to healthy subjects 82 
are rarely assessed in clinical trials due to high costs and small patient populations. The 83 
development of in vitro tools to assess the impact of CD on drug absorption could thus, improve 84 
the drug therapy of CD patients. 85 
For healthy subjects, biorelevant media closely simulating GI fluids of different GI 86 
compartments and prandial states have been developed to evaluate drug product performance 87 
in vitro using solubility or dissolution studies (Galia et al., 1998; Jantratid et al., 2008; 88 
Markopoulos et al., 2015; Vertzoni et al., 2010; Vertzoni et al., 2005). This approach has 89 
previously been extended to special populations and biorelevant media have been developed 90 
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for paediatrics or hypochlorhydric and achlorhydric people (Litou et al., 2017; Maharaj et al., 91 
2016). Since drug product performance is influenced by a multitude of factors, the results from 92 
these in vitro studies can also be used as input in physiologically-based pharmacokinetic 93 
(PBPK) models taking into account all ADME (absorption, distribution, metabolism, and 94 
excretion) processes. 95 
The aim of this study was to develop a cost- and labour-effective tool to assess the risk of 96 
altered luminal drug solubility in patients with GI diseases in vitro. Biorelevant media 97 
representative of the stomach, intestine and colon of CD patients were developed based on 98 
literature data and biorelevant media describing GI conditions in healthy subjects. Fasted and 99 
fed state conditions were considered for the intestine and also for the colon, where the different 100 
prandial states represent the extreme conditions expected in a clinical study setting. To take 101 
into account the interindividual variability in CD patients, a Design of Experiment (DoE) 102 
approach was followed. The simulated GI fluids representing patients with CD were 103 
characterised according to their surface tension, osmolality, buffer capacity and dynamic 104 
viscosity. The solubility of six drugs, belonging to BCS class II or IV and possessing different 105 
physicochemical characteristics, was assessed in CD biorelevant media. The investigated drugs 106 
were azathioprine, budesonide, celecoxib, dipyridamole, loperamide and sulfasalazine. The 107 
results of the solubility studies were analysed with partial least squares (PLS) regression to 108 
identify the impact of media-dependent factors (e.g, bile salt concentration) on the solubility 109 
of the drugs according to their physicochemical characteristics. 110 
2. Materials 111 
Acetic acid HPLC grade, methanol, pepsin from porcine gastric mucosa, sodium oleate, α-D-112 
glucose, budesonide, phosphoric acid and sodium hydroxide were purchased from Sigma-113 
Aldrich Company Ltd., Dorset, England. Sulfasalazine, loperamide hydrochloride, 114 
dipyridamole, celecoxib, azathioprine, methanol HPLC grade, acetonitrile HPLC grade and 115 
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cholic acid sodium salt were purchased from VWR International Ltd, Lutterworth, UK. 116 
Tris(hydroxymethyl)aminomethane, hydrochloric acid 36.5–38%, sodium chloride, 117 
trifluoroacetic acid (TFA), potassium dihydrogen orthophosphate and maleic acid were used 118 
from Fisher Scientific UK Ltd., Loughborough, England. Other chemicals used included 119 
sodium taurocholate (Prodotti Chimici Alimentari S.P.A., Basaluzzo, Italy), egg lecithin–120 
Lipoid EPCS (Lipoid GmbH, Ludwigshafen, Germany) and glyceryl monooleate–Rylo Mg 19 121 
(Danisco, Brabrand, Denmark). Water was ultra-pure (Milli-Q) laboratory grade. 122 
3. Methods 123 
3.1. Media development 124 
For the development of biorelevant media for patients with CD, a DoE approach (Section 3.1.2) 125 
was followed to reflect interpatient variability. Briefly, relevant differences in CD patients 126 
compared to healthy subjects were identified in literature, a low and a high concentration level 127 
was defined based on the available data and the differences were integrated as factors with two 128 
levels in the DoE. Biorelevant media based on healthy subjects were used as reference for all 129 
media properties and components that were not used as factors in the DoE. These biorelevant 130 
media reflect an average healthy subject. Since variability in the gastrointestinal fluid 131 
composition of healthy subjects has previously been reported, only parameters with an altered 132 
mean value in CD patients compared to healthy subjects were changed (Khadra et al., 2015). 133 
3.1.1. GI physiological differences in CD compared to healthy subjects 134 
A literature search was performed to identify differences in the GI fluid composition of CD 135 
patients compared to healthy subjects. Due to the low number of studies investigating the 136 
concentration of GI fluid components in CD, studies investigating parameters that are likely to 137 
impact on GI fluids were also considered e.g., bile acid pool. For parameters that were directly 138 
measured in the GI fluids, the observed range was included in the experimental design with the 139 
minimum value observed representing the low level of the factor and the maximum value 140 
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representing the high level of the factor, respectively. For parameters that were not directly 141 
measured in the GI fluids, an indirect percental approach was followed to determine the level 142 




∗ 𝑥𝐻−𝐵𝑀          (1) 144 
where 𝑥𝐶𝐷−𝐵𝑀 is the high or low level of the factor in CD media, 𝑦𝐶𝐷 and 𝑦𝐻 are the median 145 
of the corresponding parameter observed in studies of CD patients and healthy subjects, 146 
respectively and 𝑥𝐻−𝐵𝑀 is the level of the factor in biorelevant media based on healthy subjects. 147 
In the case of a decrease of the factor in CD patients compared to healthy subjects, Equation 1 148 
was used to set the low level and the high level was set to the level in biorelevant media based 149 
on healthy subjects. In the case of an increase of the factor in CD patients compared to healthy 150 
subjects, Equation 1 was used to set the high level and the low level was set to the level in 151 
biorelevant media based on healthy subjects. For the factor bile salt concentration, the bile acid 152 
pool was the corresponding parameter and for the factor colonic osmolality, the osmolality of 153 
the faecal fluid was the corresponding parameter. 154 
3.1.1.1. Bile acid pool 155 
Bile acids, after being synthesised in the liver, are secreted into bile and further undergo a 156 
process of enterohepatic recirculation including reabsorption from the terminal ileum, return 157 
to the liver and again secretion into bile (Hofmann, 1999). The physiological function of bile 158 
salts includes e.g., the elimination of cholesterol, lipid transport due to micellar solubilisation 159 
and the stimulation of bile flow and biliary phospholipid secretion (Hofmann, 1999). The bile 160 
acid pool is the total amount of bile acids circulating in the enterohepatic circulation. CD can 161 
affect any part of the gastrointestinal tract but most frequently the inflammation is localized in 162 
the terminal ileum, the main reabsorption area of bile salts. Several studies investigated the size 163 
of the bile acid pool in CD patients compared to healthy subjects, revealing a reduction to 38-164 
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58% of the size in healthy subjects as presented in Table 1 (Nishida et al., 1982; Rutgeerts et 165 
al., 1979; Vantrappen et al., 1977). The disease activity has been reported in two of the 166 
presented studies and the majority of CD patients (15 of 22) was in relapse (Rutgeerts et al., 167 
1979; Vantrappen et al., 1977). 168 
An increased loss of bile salts can be compensated by higher production. However, the constant 169 
loss of bile salt during the day, when bile salts are released in response to meals, is expected to 170 
lower the bile salt concentrations in gastrointestinal fluids. This is in line with a study by Lenz 171 
et al. (1976) revealing reduced postprandial duodenal bile acid concentrations in 9 out of 19 172 
CD patients. Bile salts are present in the luminal fluids of all gastrointestinal compartments and 173 
thus, lower bile acid concentrations were integrated in the DoE of all CD media.  174 
  175 
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Table 1: Bile acid pool in CD patients and controls [mean (SD)]. 176 
 Bile acid pool 
healthy [g] 






 2.29 (0.33) 1.32 (0.17) 8/4 (Nishida et al., 
1982) 
 3.09 (0.27) 1.48 (0.16) 10/14 (Vantrappen et al., 
1977)  
 3.10 (0.27) 1.18 (0.20) 13/10 (Rutgeerts et al., 
1979) 
Median 3.09 1.32   
3.1.1.2. pH in the stomach 177 
The pH profile in the stomach of CD patients was in the range of pH 1.5 to 4.1 as investigated 178 
in two studies with the majority of patients (20 out of 27) being in an active disease state (Ewe 179 
et al., 1999; Press et al., 1998). A higher pH was also indicated by a reduced gastric acid 180 
secretion observed in CD patients, being especially strong if patients were malnourished with 181 
a mean basal acid output of 0.64 ± 0.33 mEq/h (malnourished) and 2.12 ± 0.88 mEq/h (after 182 
nutritional support) vs 3.85 ± 0.93 mEq/h in controls and a maximal acid output of 183 
7.36 ± 1.38 mEq/h (malnourished) and 12.76 ± 2.50 mEq/h (after nutritional support) vs 184 
25.53 ± 4.58 mEq/h in controls (Winter et al., 2004). 185 
3.1.1.3. Osmolality in the colon 186 
The faecal osmolality in CD patients was increased by 32% to 52% as observed in two studies 187 
and presented in Table 2 (Schilli et al., 1982; Vernia et al., 1988). Apart from higher sodium 188 
and chloride concentrations, this observation was also accompanied with a large osmotic gap 189 
indicating osmotic diarrhoea in CD patients from osmotic active agents other than electrolytes 190 
such as undigested carbohydrates. Since these undigested components are already present in 191 
the large intestine, an increased osmolality in the colon is expected for patients with CD. A 192 
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higher osmolality in colonic luminal fluids was reflected by integrating the osmolality as factor 193 
in the DoE of colonic CD media. 194 
 195 
Table 2: Osmolality of the faecal fluids of CD patients and controls [mean values (SD or 196 
range)]. 197 
 Osmolality in CD 
[mOsm/kg] 






 487 (SD 87) 321 (range 254-464) 13/11 (Schilli et al., 
1982) 
 463 (SD 21) 350 (SD 20) 20/16 (Vernia et al., 
1988) 
Median 475 336   
3.1.2. Design of CD media with Design of Experiment 198 
The media development for CD patients followed a DoE approach. Biorelevant media 199 
developed for healthy subjects (Table 3) were used as reference and modifications were made 200 
to reflect the changes in the composition of luminal contents in patients with CD (Section 201 
3.1.1). For the gastric medium in the fasted state, pH (p) and bile salt (b) concentration were 202 
included as factors in the DoE. As previously reported for healthy subjects, low bile salt 203 
concentrations in the stomach are expected to originate from occasional bile salt reflux from 204 
the small intestine to the stomach.13 For intestinal media, the bile salt (b) concentration was 205 
included as single factor. For colonic media, osmolality (o) and bile salt (b) concentration were 206 
included as factors. The DoE was performed using XLSTAT (Addinsoft, France) with a full 207 
factorial design in CD patients for stomach, intestine, colon in the fasted state and intestine and 208 
colon in the fed state. Each parameter changed in CD compared to healthy subjects was 209 
integrated in the DoE as factor with two levels, low (l) and high (h), resulting in 17 CD media 210 
(Figure 1): 211 
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- CD- Fasted-State Simulated Gastric Fluid (FaSSGF): changed parameters pH, bile salts 212 
(lp-lb, hp-lb, lp-hb, hp-hb) 213 
- CD- Fasted-State Simulated Intestinal Fluid (FaSSIF): changed parameter bile salts 214 
(only one medium, high bile salt medium corresponds to FaSSIF-V2) 215 
- CD- Fasted-State Simulated Colonic Fluid (FaSSCoF): changed parameters osmolality, 216 
bile salts (lb-lo, hb-lo, lb-ho, hb-ho) 217 
- CD- Fed-State Simulated Intestinal Fluid (FeSSIF): changed parameter bile salts (only 218 
one medium, high bile salt medium corresponds to FeSSIF-V2) 219 
- CD- Fed-State Simulated Colonic Fluid (FeSSCoF): changed parameters osmolality, 220 
bile salts (lb-lo, hb-lo, lb-ho, hb-ho) 221 
Additionally, a centre point with medium (m) levels of each parameter was included for CD-222 
FaSSGF (mp-mb), CD-FaSSCoF (mb-mo) and CD-FeSSCoF (mb-mo).  223 
In terms of the levels set for the factors in the DoE, the pH range observed in the stomach of 224 
CD patients was included with 1.5 as low level and 4.1 as high level for fasted state gastric CD 225 
media (Section 3.1.1.2). For the bile salt concentrations in all CD media, the low level was set 226 
based on the percental approach described in Section 3.1.1 corresponding to 43% of the 227 
concentration in the corresponding healthy biorelevant media. The ratio of bile salts to lecithin 228 
was kept constant in all CD media and set according to the ratio in healthy biorelevant media 229 
(Table 3), in order to reflect the mixed micelles in GI fluids. For the osmolality in the colonic 230 
CD media, the high level was based on the percental difference (Section 3.1.1) with 142% of 231 
the osmolality in corresponding healthy biorelevant media. Sodium chloride was used to adjust 232 
the osmolality in the respective colonic CD media. For all other CD media (osmolality not 233 
included as factor in the DoE), the osmolality was adjusted to the value of the corresponding 234 
healthy biorelevant medium.  235 
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The method described by Jantratid et al. (2008) was followed for the preparation of gastric and 236 
intestinal biorelevant media. Colonic biorelevant media were prepared according to Vertzoni 237 
et al. (2010).  238 
 239 
Table 3: Biorelevant media representing conditions in healthy subjects. 240 
Medium FaSSGF FaSSIF-V2 FaSSCoF FeSSIF-V2 FeSSCoF 
Sodium chloride [mM] 34.20 68.60  125.50 34.00 
1M HCl qs pH 1.60     
Sodium taurocholate 
[mM] 
0.08 3.00  10.00  
Lecithin [mM] 0.02 0.20 0.36 2.00 0.50 
Pepsin [mg/mL] 0.10     
Maleic acid [mM]  19.10 75.80 71.90 30.15 
NaOH [mM]  34.80 120.00 102.40 16.50 
Sodium cholate [mM]   0.15  0.60 
Tris [mM]   45.40  30.50 
Sodium oleate [mM]   0.10 0.80 0.20 
Glycerol monooleate 
[mM] 
   5.00  
Glucose [mg/ml]     14.00 
Osmolality [mOsm/kg] 121 180 196 390 207 
pH 1.6 6.5 7.8 5.8 6.0 















3.2. Media characterisation  242 
Healthy biorelevant media and biorelevant media developed for CD were characterised 243 
according to their surface tension, osmolality, dynamic viscosity and buffer capacity. All 244 




3.2.1. Surface tension  247 
A Du Noüy ring tensiometer (Sigma 700 Force tensiometer, Attension, UK) was used to 248 
measure the surface tension of biorelevant media at room temperature. The surface tension of 249 
the medium can be related to the measured force according to equation (2) with 250 
𝐹 = 𝑤𝑟𝑖𝑛𝑔 + 2𝜋 ∗ (𝑟𝑖 + 𝑟𝑎) ∗ 𝛾        (2) 251 
where 𝐹 is the force, 𝛾 is the surface tension, 𝑤𝑟𝑖𝑛𝑔 is the weight of the ring and 𝑟𝑖 and 𝑟𝑎 are 252 
the inner and outer radius of the ring, respectively (Butt et al., 2004). 253 
3.2.2. Osmolality  254 
The osmolality of the media was determined with an Advanced Instruments Inc. micro-255 
osmometer Model 3300 (Norwood, MA, US) by measuring the freezing-point depression of a 256 
20 µl sample. After the supercooling of the sample, crystallisation was induced by mechanical 257 
agitation and the temperature when the sample was in a solid/liquid equilibrium was measured. 258 
Osmolality was subsequently calculated since freezing-point depression is a colligative 259 
property (freezing point depression by 1.858 m°C corresponds to 1 mOsm/kg). 260 
3.2.3. Dynamic viscosity  261 
Dynamic viscosity was measured with a Bohlin Rheometer C-VOR (Malvern instruments, UK) 262 
using a cone-plate system (4°,40 mm). A range of shear stresses (20 points, logarithmically 263 
distributed between 0.05 and 0.15 Pa) were applied to the sample of the medium tempered at 264 
37⁰C and the shear rate was measured. Dynamic viscosity was calculated as the ratio of shear 265 
stress to shear rate. 266 
3.2.4. Buffer capacity 267 
Buffer capacity was measured by subsequently adding volumes of 0.5 M hydrochloric acid to 268 
10 mL sample until a change of one pH unit was recorded by a Mettler Toledo SevenCompact 269 
S220 pH meter (Schwerzenbach, Switzerland). The buffer capacity (β) was calculated using 270 









        (3) 272 
where Macid is the molarity of the acid used, Vacid is the added volume of the acid, Vsample is the 273 
volume of the sample and ΔpH corresponds to the change in pH (Rabbie et al., 2015).  274 
3.3. Compound selection 275 
For the solubility studies, poorly soluble compounds belonging to BCS class II (low solubility, 276 
high permeability) or IV (low solubility, low permeability) were selected as presented in Table 277 
4. While drugs with an indication for GI diseases were preferred, the main selection criterion 278 
was to cover a range of different physicochemical properties. Therefore, we included 279 
moderately lipophilic drugs that varied in their ionisation properties: budesonide as neutral 280 
drug, dipyridamole and loperamide as weak bases and sulfasalazine as weak acid. Additionally, 281 
we included drugs that were mainly neutral over the physiological pH range but varied in their 282 
lipophilicity: azathioprine with a low logP and celecoxib with a high logP. Due to the pKa of 283 
7.9, azathioprine is considered as neutral drug in all media except the fasted state colonic media 284 
(pH of 7.8), where it is considered as weak acid.  285 
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et al., 2004) 
Immunosuppressive 























et al., 2001) 
Nonsteroidal anti-
inflammatory drug 

















II (Zaki et 
al., 2010) 
Anti-diarrheal agent 
Sulfasalazine 398.4 2.3, 7.9 
(acid) 
(Shalaeva et 







et al., 2004) 
Anti-inflammatory 
agent in IBD 
 287 
3.4. Solubility studies 288 
The solubility studies of the investigated drugs were performed using the shake-flask method 289 
(Baka et al., 2008). Therefore, 5 mL of medium were transferred to a glass tube with an excess 290 
amount of drug. The glass tube was placed for 24 h in a shaking water bath (Grant instruments, 291 
Royston, UK) (37°C, 200 strokes/min). Subsequently, the sample was filtered with GF/D 292 
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membrane filters with a pore size of 2.7 μm (Whatman® Puradisc, diameter 13 mm) and 293 
analysed by HPLC- UV. Solubility studies were performed in triplicate in 17 CD media and 294 
for comparison in 5 healthy media. Average solubility differences between CD media and 295 
healthy media were expressed as a % Relative effect on solubility [((SCD-SHealthy)/ SHealthy) x 296 
100)]. Positive values indicate that drug solubility in CD media exceeds the solubility in healthy 297 
media, whereas negative values indicate the opposite. HPLC analysis was performed with an 298 
Agilent Technologies 1200 series HPLC system (Santa Clara, CA): binary pump (G1212A), 299 
autosampler (G1329A), thermostatted column compartment (G1316A) and diode array 300 
detector (G1315D). HPLC-UV methods used for the quantitative analysis are presented in 301 
Table 5.  302 
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Table 5: HPLC/UV analytical methods used for the quantification of the investigated drugs. 303 


















80 Å, 250 x 




0.1% in H2O 
75:25 v/v  







80 Å, 150 x 




3.3% in H2O 
70:30 v/v 
1 20 50 359 
Azathioprine 




C18, 100 Å, 




1% in H2O 
65:35 v/v 






C18, 100 Å, 















80 Å, 250 x 








130 Å, 150 x 
4.6 mm, 3.5 
µm 
ACN: TFA 
0.1% in H2O 
30:70 v/v 




3.5. Statistical analysis 305 
One-way analysis of variance (ANOVA) with a post-hoc Tukey’s test was applied to identify 306 
statistically significant differences of media properties and drug solubility between biorelevant 307 
media based on healthy subjects and various biorelevant media of CD patients. Therefore, the 308 
software XLSTAT (Addinsoft, France) was used with a significance level of p≤0.05. 309 
Multivariate statistical analysis was used to identify drugs at risk of altered drug solubilisation 310 
in CD according to the physicochemical properties of the drug. Therefore, the % Relative effect 311 
on drug solubility ((SCD-SHealthy)/ SHealthy) x 100) was correlated with media-dependent factors 312 
of the DoE and drug physicochemical properties by Partial Least Squares (PLS) regression 313 
using the software XLSTAT (Addinsoft, France). Media-dependent factors were for gastric 314 
fasted state CD media the bile salt concentration and pH, for intestinal CD media in the fasted 315 
and fed state only the bile salt concentration and for colonic CD media in both prandial states 316 
the bile salt concentration and osmolality. In terms of drug-dependent parameters, the partition 317 
coefficient, log P, derived from literature (Table 4) was included for all CD media. For media 318 
with pH as media-dependent factor (CD-FaSSGF), a categorical variable discriminating 319 
between weak acids, weak bases and neutral compounds was introduced. For the remaining 320 
CD media (CD-FaSSIF, CD-FaSSCoF, CD-FeSSIF, CD-FeSSCoF), the % Fraction ionised 321 
(calculated using Advanced Chemistry Development, Inc. (ACD/Labs) Software V11.02, 322 
Toronto, On, Canada and defined for anionic species as negative and cationic species as 323 
positive), was integrated as additional drug-dependent factor (Advanced Chemistry 324 
Development Inc., 2019). Interactions between media-dependent and drug-dependent factors 325 
were included in the model. The quality of the obtained models was evaluated based on the 326 
square of coefficient of determination (r2) and goodness of prediction (q2), indicating when 327 
close to 1 a good fit of the data and a good predictive ability of the model, respectively. Highly 328 
disparate r2 and q2 (difference higher than 0.3) indicate inappropriate models due to model 329 
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over-fitting. (Eriksson et al., 2008) Models were selected based on the minimum predicted 330 
residual error sum of squares (PRESS) and the highest q2 representing optimum model 331 
predictability. A q2 higher than 0.5 generally indicates good model predictability, but it should 332 
be noted that q2 is dependent on the properties of the data set, thereby impeding the setting of 333 
a general limit (Triba et al., 2015). The effect of media- and drug-dependent factors on the 334 
% Relative effect on solubility is shown by their standardised coefficients with high values 335 
designating a considerable influence, positive values designating a positive effect and negative 336 
values a negative effect, respectively. Factors with a Variable Importance in Projection (VIP) 337 
higher than or equal to 0.7 are the most influential factors in the model and were considered as 338 
statistically significant (Eriksson et al., 2008). 339 
4. Results and discussion 340 
4.1. Media characterisation 341 
Surface tension of biorelevant media based on CD patients and healthy subjects is presented in 342 
Figure 2. In gastric media, the surface tension was significantly higher in all CD-FaSSGF 343 
media (hp-hb +12%, mp-mb +13%, lp-lb +15%, hp-lb +24%,) except CD-FaSSGF lp-hb 344 
compared to FaSSGF (p<0.05). A higher surface tension of CD-FaSSGF media with low and 345 
medium bile salt and lecithin concentrations could be due to bile salt and lecithin 346 
concentrations being below the critical micellar concentration (CMC). The higher surface 347 
tension of CD-FaSSGF hp-hb could be related to the different salt composition, since less 348 
hydrochloric acid and a higher concentration of sodium chloride was used compared to the 349 
healthy medium. The surface tension has been reported to increase with a higher salt 350 
concentration due to solute depletion at the interface (Hsin et al., 2004). 351 
For fasted state intestinal media, the surface tension of the CD medium was significantly 352 
increased by 9% compared to the corresponding healthy medium (p<0.05). This is in agreement 353 
with a previous study showing a higher surface tension for fasted state simulating fluids with 354 
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reduced bile salt concentrations (Xie et al., 2014). Considering the surface tension of fasted 355 
state colonic media, only for CD-FaSSCoF lb-ho the surface tension was significantly 356 
decreased by 8% compared to FaSSCoF (p<0.05). In fed state intestinal media, the CD medium 357 
showed a significantly lower surface tension (-8%) compared to FeSSIF-V2. This slight 358 
decrease in surface tension with lower sodium taurocholate concentration has previously been 359 
observed for fed state simulated intestinal fluids in a range of 1-7 mM (Xie et al., 2014). For 360 
fed state colonic media, the surface tension of CD-FeSSCoF mb-mo, lb-lo, lb-ho was 361 
significantly decreased by -11%, -22% and -28%, respectively compared to the corresponding 362 
healthy medium (p<0.05).  363 
Osmolality in CD fasted state gastric and intestinal media and fed state intestinal media was 364 
similar to the corresponding healthy biorelevant media as presented in Figure 2. Differences in 365 
osmolality were observed when osmolality was integrated as factor in the DoE according to 366 
the specified levels, which was the case for fasted and fed state colonic CD media. The altered 367 
osmolality in the colonic media can have an impact on the dissolution rate of certain drugs due 368 
to a common ion effect and therefore, the conversion of the drug to another salt.55 Additionally, 369 
osmolality can affect the swelling behaviour of polymers possibly due to ion exchange and 370 
thus, drug release can be slowed down with increased osmolality (Jantratid et al., 2008; Wagner 371 
and McGinity, 2002). 372 
The dynamic viscosity of CD biorelevant media at three different shear stresses is presented in 373 
Figure 3. All investigated biorelevant media showed pseudoplastic behaviour. With an applied 374 
shear stress of 0.06 Pa, the dynamic viscosity of CD biorelevant media was in the range of 4.23 375 
mPas to 6.67 mPas. An increase of the shear stress to 0.08 Pa and 0.15 Pa, resulted in a reduced 376 
viscosity in the range of 3.36 mPas to 4.92 mPas and 2.86 mPas to 3.85 mPas, respectively. 377 
Significant differences with application of the three different shear stresses were only observed 378 
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for all CD-FaSSGF media, which possessed a significantly higher viscosity compared to 379 
FaSSGF (p<0.05). 380 
Buffer capacity was not altered in intestinal and colonic CD media compared to the 381 
corresponding media based on healthy subjects due to the use of the same buffer system and 382 
no changes in pH value (data not shown). 383 
4.2. Solubility of drugs in CD biorelevant media 384 
The solubility of six different drugs was investigated biorelevant media based on CD patients 385 
and healthy subjects simulating stomach, small intestine and colon in the fasted state and small 386 
intestine and colon in the fed state. Drug solubility of all investigated drugs in biorelevant 387 
media based on healthy subjects is presented in Table 6. 388 
Table 6: Mean drug solubility (SD) of investigated drugs in biorelevant media developed to 389 
represent the GI conditions in healthy subjects (the final medium pH at 24 h is reported).  390 
  Solubility in "healthy" biorelevant media [μg/mL], {final pH} 





























































* {1.6} 1.28 (0.03) x 
103 {6.2} 
7.34 (0.11) x 
103 {6.7} 




*Measurement value of 1.17 ug/mL (>LOD, <LOQ) was only used as reference for 391 
comparative purposes 392 
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In fasted state gastric media, differences in drug solubility between biorelevant media based on 393 
CD patients and healthy subjects were observed (Figure 4). The solubility of the weak acid 394 
sulfasalazine was significantly increased in CD gastric media with high pH (p<0.05) as a higher 395 
fraction of the drug was ionised. For the weak base dipyridamole, the solubility was 396 
significantly decreased in CD gastric media with high and medium pH and increased in CD 397 
gastric media with low pH (p<0.05), indicating also a higher solubility with increasing 398 
ionisation of the drug. The solubility of loperamide hydrochloride, another weak base, was 399 
significantly increased in CD gastric media with high pH and low bile salt concentrations, most 400 
probably due to the common ion effect since less chloride ions are present in the gastric CD 401 
media with high pH (less hydrochloric acid), and decreased in CD gastric media with low pH 402 
and high bile salt concentrations (p<0.05). For neutral compounds, significant differences in 403 
drug solubility in CD gastric media were only observed for budesonide with a lower solubility 404 
in all CD gastric media compared to FaSSGF (p<0.05).  405 
The % Relative effect of CD on drug solubility in fasted and fed state intestinal media is shown 406 
in Figure 5. In fasted state intestinal media, the solubility of celecoxib and the weak bases, 407 
loperamide hydrochloride and dipyridamole, was significantly lower in CD intestinal media 408 
(p<0.05). This is in accordance with another study showing an impact of bile salt and lecithin 409 
concentration on the solubility of four weak bases and four neutral compounds in fasted state 410 
simulated intestinal fluids (Khadra et al., 2015). Therefore, relevant differences in drug 411 
solubilisation in CD are expected for neutral lipophilic compounds and moderately lipophilic 412 
weak bases. The higher impact of reduced bile salt concentrations on weak bases could be 413 
explained by an interaction of the protonated drug with the charged head group of sodium 414 
taurocholate (Niederquell and Kuentz, 2018). 415 
In fed state intestinal media, the solubility of sulfasalazine, dipyridamole, celecoxib and 416 
loperamide hydrochloride was significantly decreased in CD media (p<0.05). The solubility of 417 
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budesonide was lower in CD-FeSSIF but the difference was not statistically significant 418 
(p=0.06). Drug solubilisation of hydrophilic drugs, such as azathioprine, is not expected to be 419 
altered in CD-FeSSIF. For moderately to highly lipophilic drugs, a decrease in drug 420 
solubilisation is expected in fed state intestinal CD media, irrespective of their ionisation 421 
properties. 422 
The % Relative effect of CD on the solubility of investigated drugs in colonic biorelevant media 423 
in the fasted state and fed state is shown in Figure 6. In colonic media in the fasted state, the 424 
CD biorelevant medium with high bile salt concentration and low osmolality corresponds to 425 
FaSSCoF. In colonic media in the fed state, the CD biorelevant medium with high bile salt 426 
concentration and low osmolality corresponds to FeSSCoF. The solubility of loperamide 427 
hydrochloride and budesonide was significantly decreased in all CD-FaSSCoF media 428 
compared to FaSSCoF (p<0.05). The solubility of dipyridamole was significantly decreased in 429 
CD-FaSSCoF with low bile salt concentrations and high osmolality (p<0.05). The solubility of 430 
celecoxib was significantly lower in CD-FaSSCoF media with low bile salt concentrations 431 
(p<0.05). As for CD-FaSSIF, the results suggest a lower solubility of moderately and highly 432 
lipophilic neutral and weakly basic compounds as a result of decreased bile salt and lecithin 433 
concentrations in CD fasted state colonic media. Additionally, increased osmolality had a 434 
negative impact on drug solubility of loperamide hydrochloride and budesonide. For 435 
loperamide, this can be attributed to a common ion effect due to the higher chloride 436 
concentration. The higher osmolality of the faecal fluid of CD patients was not only 437 
accompanied with a higher concentration of sodium and chloride but also with an increased 438 
osmotic gap, indicating an increased concentration of insoluble carbohydrates (Vernia et al., 439 
1988). Since sodium chloride was used to change the medium’s osmolality, the impact of the 440 
altered osmolality on the solubility of loperamide hydrochloride could be slightly lower.   441 
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In fed state colonic media, the solubility of sulfasalazine was decreased in all CD media (p<0.5) 442 
suggesting a negative impact of decreased bile salt and lecithin concentration and increased 443 
osmolality on the solubility of sulfasalazine. The solubility of loperamide hydrochloride and 444 
celecoxib was decreased in CD media with low or medium bile salt concentrations (p<0.5). 445 
The solubility of dipyridamole was decreased in CD-FeSSCoF with low bile salt concentration 446 
and low osmolality (p<0.5). The results suggest a decreased solubility for neutral and weakly 447 
acidic drugs with high lipophilicity in media with lower bile salt and lecithin concentrations 448 
also in CD-FeSSCoF media. 449 
4.3. Multivariate statistical analysis 450 
The PLS models for the different GI compartments and prandial states are shown in Figure 7 451 
with the standardised coefficients and VIPs of the respective drug- and media-dependent 452 
factors and their interactions. For the fasted state gastric media, the developed PLS model for 453 
the % Relative effect of CD on drug solubility showed a good fit of the experimental data (r2 454 
0.89) and a high predictive power (q2 0.79). The model depicted a positive effect of the 455 
categorical variable weak acid, of the pH and of the interplay between pH and weak acid. In 456 
contrast, the categorical variable of neutral compounds had a negative effect on drug solubility. 457 
For fasted state intestinal media, the PLS model with good model quality (r2 0.78, q2 0.71) 458 
revealed a positive effect of bile salts and of the interplay between bile salts and log P, while 459 
the log P had a negative effect on the % Relative effect of CD on drug solubility. This suggests 460 
that drug solubilisation of lipophilic compounds is at risk in CD patients with low intestinal 461 
bile salt concentrations. 462 
For fasted state colonic media, a predictive PLS model was developed (r2 0.57, q2 0.50). 463 
According to the model, the % Relative effect of CD on drug solubility was negatively 464 
influenced by % Fraction ionised and log P, while bile salts and the interplay between bile salts 465 
and % Fraction ionised showed a positive influence. The positive influence of the interplay 466 
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between bile salts and % Fraction ionised can be explained by the interaction between the 467 
cationic fraction of the weak bases and the headgroup of sodium taurocholate. 468 
For fed state intestinal media, the PLS model (r2 0.60, q2 0.51) showed that bile salts had a 469 
positive effect on drug solubility. 470 
For fed state colonic media, the predictive power of the developed PLS model was low (q2 0.37) 471 
and the model could only account for a low percentage of variability in the dependent variable 472 
(r2 0.42). Important variables of the model were bile salts and the interplay of bile salts and 473 
log P with a positive effect and log P with a negative effect on the % Relative effect of CD on 474 
drug solubility. 475 
4.4. Drugs at risk of altered solubility in luminal fluids of CD patients 476 
In simulated gastric fluids of CD patients compared to biorelevant media based on healthy 477 
subjects, differences of drug solubility were observed for a weak acid and weak bases. 478 
Therefore, an altered gastric pH in CD is expected to pose a risk for ionisable drugs. For weak 479 
acids, an increased gastric pH in CD patients is expected to result in a higher drug solubility. 480 
For drugs with moderate to high lipophilicity, a high risk of altered drug solubilisation is 481 
expected in the fasted state intestinal fluids of CD patients with low bile salt and lecithin 482 
concentrations. In contrast, hydrophilic drugs have a low risk of altered drug solubility in 483 
intestinal fluids of CD patients as shown by a similar drug solubility of azathioprine in intestinal 484 
biorelevant based on CD patients and healthy subjects. 485 
Considering colonic fluids of CD patients, a reduced drug solubility is expected with an 486 
increased log P in the fasted and fed state as indicated by the PLS models (Section 4.3), 487 
especially when low bile salt and lecithin concentrations are present in the colonic fluids of CD 488 
patients. Drugs that are at the same time also weak bases possess a higher risk for a reduced 489 
drug solubility in the fasted state colonic fluids as indicated by the negative effect of the % 490 
Fraction ionised in the respective PLS model.     491 
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Given the high number of CD media, solubility studies with six compounds were performed 492 
and resulted in appropriate statistical models. 493 
 494 
5. Conclusion  495 
Simulating the conditions in CD patients in vitro offers the possibility to identify relevant 496 
differences in drug solubilisation without conducting clinical trials. Especially for drugs for 497 
concomitant diseases, drug product performance is rarely investigated in CD patients due to 498 
the high costs associated with clinical trials. For the local treatment of CD in the GI tract, drug 499 
release/ dissolution and solubility are particularly relevant since high drug concentrations need 500 
to be achieved at the target site. The presented simulated media for CD patients can further be 501 
used for drug release/dissolution studies and results can be integrated in mechanistic PBPK 502 
models to consider additional pathophysiological differences (e.g., permeability, distribution, 503 
gut wall/hepatic metabolism and elimination) regarding all ADME processes in order to predict 504 
a drug’s plasma concentration profile in vivo. 505 
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Figure Legends 678 
Figure 1: Design of Experiment for the development of biorelevant media for CD patients. 679 
Figure 2: Surface tension (blue, left y-axis) and osmolality (red, right y-axis) of CD 680 
biorelevant media according to the Design of Experiments (green: high level, yellow: 681 
medium level, red: low level, white: healthy) and biorelevant media based on healthy 682 
subjects. 683 
Figure 3: Dynamic viscosity of CD biorelevant media according to the Design of 684 
Experiments (green: high level, yellow: medium level, red: low level, white: healthy) and the 685 
corresponding biorelevant media based on healthy subjects at different shear stress (0.06 Pa: 686 
blue, 0.08 Pa: red, 0.15 Pa: black). 687 
Figure 4: % Relative effect (RE) on solubility of investigated drugs in CD gastric biorelevant 688 
media according to the Design of Experiments (green: high level, yellow: medium level, red: 689 
low level) in the fasted state compared to the corresponding medium based on healthy 690 
subjects. 691 
Figure 5: % Relative effect (RE) on solubility of investigated drugs in CD intestinal 692 
biorelevant media in the fasted state and fed state compared to the corresponding media based 693 
on healthy subjects. 694 
Figure 6: % Relative effect (RE) on solubility of investigated drugs in CD colonic biorelevant 695 
media in the fasted state (top) and fed state (bottom) according to the Design of Experiments 696 
(green: high level, yellow: medium level, red: low level) compared to the corresponding 697 
media based on healthy subjects. 698 
Figure 7: Standardised coefficients of the PLS regression of drug solubility in CD simulated 699 
gastrointestinal fluids in the fasted state (left) and fed state (right) and different compartments 700 
35 
 
of the GI tract (top: stomach, middle: small intestine, bottom: colon). Red colour denotes 701 
coefficients of VIP values > 1, green > 0.7 and blue < 0.7. 702 
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